A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Trial Profile

A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary) ; Paricalcitol (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2018 Results (n=10) assessing efficacy and safety of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) NAPPCG in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC), were presented at the 2018 Gastrointestinal Cancers Symposium.
    • 15 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top